US Pharma MarketingThe post ViiV’s two-monthly HIV jab bests daily oral drugs in African teenagers appeared first on Clinical Trials Arena.
ViiV’s two-monthly HIV jab bests daily oral drugs in African teenagers
ViiV Healthcare's LATA study pitted Cabenuva against a triple therapy in teenagers aged 12 to 19 with HIV in Africa. The post ViiV’s two-monthly HIV jab bests daily oral drugs in African teenagers appeared first on Clinical Trials Arena .
ViiV Healthcare's LATA study pitted Cabenuva against a triple therapy in teenagers aged 12 to 19 with HIV in Africa.
Source: Clinical Trials Arena